Editing PHKG Business Opportunities (section)

=== Market Context ===

'''Existing players:'''

'''Klinik Healthcare Solutions''' (Finland, founded 2013) — the serious incumbent. CE-marked, deployed across NHS GP practices in England. AI patient flow management that routes patients to appropriate care. Independent health-economic evaluation by York Health Economics Consortium at Priory Medical Group: enabled delivery of 18 months' appointments in one year, £300k+ capacity savings. '''However:''' Finnish entity reported €1.49M revenue and €701k loss in FY2023, revenue down 6.1%, headcount down 14.3%. UK revenue likely booked separately. This is a signal about category willingness-to-pay, not just execution.<ref>Tracxn: Klinik Healthcare Solutions — https://tracxn.com/d/companies/klinik-healthcare-solutions/__IbnQBw_2bEtdpWPMAMu_HZcJ4LnkpBj8IqOy8BRCGs</ref>

'''NHS England incumbents:''' The UK is not a greenfield. AccuRx, eConsult, Patchs, and Anima are already widely deployed across NHS GP practices. The NHS Long Term Plan effectively mandated electronic triage forms. These represent the realistic competitive set if Stamen targets UK or follows UK-style procurement in the Nordics.

'''Ada Health''' (Germany, $100M+ raised) — AI symptom assessment with 30K+ medical concepts. B2C app, not integrated into GP workflow. Different product (patient-facing diagnosis vs. GP-assistant triage).

'''Babylon Health''' (UK, $4B peak valuation → collapsed) — AI triage + telehealth. Failed due to overpromising and regulatory issues. Warning story: don't position as "AI doctor."

'''Your.MD''' (Norway/UK) — AI symptom checker. Pivoted, limited traction.

'''What's different:'''
* Ada and Babylon are standalone symptom checkers. They compete with the GP, not assist the GP.
* Klinik and NHS incumbents do static questionnaire triage. A PHKG-backed version with LLM-based structured history-taking is a different product.
* The LLM-augmented version is genuinely new and promising. The static-questionnaire version has a 25-year history of underwhelming results (see RCT evidence below).'''